IP Verse

(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof - EP2962690

The patent EP2962690 was granted to Amgen Europe on Jan 16, 2019. The application was originally filed on Mar 20, 2003 under application number EP15177140A. The patent is currently recorded with a legal status of "Revoked".

EP2962690

AMGEN EUROPE
Application Number
EP15177140A
Filing Date
Mar 20, 2003
Status
Revoked
Jan 22, 2025
Grant Date
Jan 16, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (15)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFRED E TIEFENBACHEROct 16, 2019ADMISSIBLE
CIPLAOct 16, 2019ADMISSIBLE
DR REDDYS LABORATORIESOct 16, 2019ADMISSIBLE
GALENICUM HEALTH SLUOct 16, 2019ADMISSIBLE
KRKAOct 16, 2019ADMISSIBLE
STADA ARZNEIMITTELOct 16, 2019ADMISSIBLE
ZENTIVA KSOct 16, 2019ADMISSIBLE
HEXALOct 15, 2019ADMISSIBLE
QUIMICA SINTETICAOct 15, 2019ADMISSIBLE
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETIOct 15, 2019ADMISSIBLE
GENERICS UKOct 11, 2019ADMISSIBLE
POLPHARMAOct 11, 2019ADMISSIBLE
ACCORD HEALTHCAREOct 10, 2019ADMISSIBLE
HOFFMANN EITLEOct 10, 2019ADMISSIBLE
TEVA PHARMACEUTICALSOct 3, 2019ADMISSIBLE

Patent Citations (27) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS3536809
DESCRIPTIONUS3598123
DESCRIPTIONUS3845770
DESCRIPTIONUS3916899
DESCRIPTIONUS4008719
DESCRIPTIONUS5059595
DESCRIPTIONUS5073543
DESCRIPTIONUS5120548
DESCRIPTIONUS5354556
DESCRIPTIONUS5591767
DESCRIPTIONUS5639476
DESCRIPTIONUS5674533
DESCRIPTIONUS5733566
DESCRIPTIONUS6020358
EXAMINATIONEP1752148
OPPOSITIONEP0238044
OPPOSITIONEP1485087
OPPOSITIONEP1752148
OPPOSITIONEP2074995
OPPOSITIONEP2962690
OPPOSITIONEP6023050
OPPOSITIONUS366515
OPPOSITIONUS6020358
OPPOSITIONUS6025376
OPPOSITIONWO0025777
OPPOSITIONWO03080049
SEARCHUS6020358

Non-Patent Literature (NPL) Citations (116) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AU ET AL., BRIT. J. PHARM., (1998), vol. 123, pages 1260 - 1266-
DESCRIPTION- BAEBR ET AL., J. BIOL. CHEM., (1979), vol. 254, page 11669-
DESCRIPTION- BAUGHMAN ET AL., J. LAB. CLIN. MED., (1990), vol. 115, pages 36 - 42-
DESCRIPTION- BEAVO; REITSNYDER, TRENDS IN PHARM., (1990), vol. 11, pages 150 - 155-
DESCRIPTION- BERTOLINI ET AL., NATURE, (1986), vol. 319, pages 516 - 518-
DESCRIPTION- BISSONNETTE ET AL., INFLAMMATION, (1989), vol. 13, pages 329 - 339-
DESCRIPTION- BLOOM; BEAVO, PROC. NATL. ACAD SCI. USA, (1996), vol. 93, pages 14188 - 14192-
DESCRIPTION- BURGER MEDICINAL CHEMISTRY AND DRUG DISCOVERY, (1995), pages 172 - 178,949-982-
DESCRIPTION- CLOUSE ET AL., J. IMMUNOL., (1989), vol. 142, pages 431 - 438-
DESCRIPTION- CORRAL ET AL., MOL. MED, (1996), vol. 2, pages 506 - 515-
DESCRIPTION- Current Medical Diagnosis & Treatment, APPLETON & LANGE, (1998), page 499-
DESCRIPTION- DERIAN ET AL., J. IMMUNOL., (1995), vol. 154, pages 308 - 3 17-
DESCRIPTION- DERIAN ET AL., J. IMMUNOL., (1995), vol. 154, pages 308 - 317-
DESCRIPTION- DEZTIBE ET AL., LANCET, (1990), vol. 335, page 662-
DESCRIPTION- DUH ET AL., PROC. NAT. ACAD. SCI., (1989), vol. 86, pages 5974 - 5978-
DESCRIPTION- ELLIOT ET AL., INT. J. PHARMAC., (1995), vol. 17, pages 141 - 145-
DESCRIPTION- FERRAI-BALIVIERA, ARCH. SURG., (1989), vol. 124, pages 1400 - 1405-
DESCRIPTION- FOLKS ET AL., PNAS, (1989), vol. 86, pages 2365 - 2368-
DESCRIPTION- GEORGE MULLER ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (1999), vol. 9, pages 1625 - 1630-
DESCRIPTION- GILLESPIE ET AL., MOL. PHARM., (1989), vol. 36, page 773-
DESCRIPTION- GRAU ET AL., N. ENGL. J. MED., (1989), vol. 320, pages 1586 - 1591-
DESCRIPTION- HATZELMANN; SCHUDT, J. PHARM. EXP. THER., (2001), vol. 297, pages 267 - 279-
DESCRIPTION- HIDAKA; ASANO, BIOCHEM. BIOPHYS. ACTA, (1976), vol. 429, page 485-
DESCRIPTION- HINSHAW ET AL., CIRC. SHOCK, (1990), vol. 30, pages 279 - 292-
DESCRIPTION- HOLLER ET AL., BLOOD, (1990), vol. 75, pages 1011 - 1016-
DESCRIPTION- JENS T. CARSTENSEN, Drug Stability: Principles & Practice, MARCEL DEKKER, (1995), pages 379 - 80-
DESCRIPTION- JOHNSON ET AL., ENDOCRINOLOGY, (1989), vol. 124, pages 1424 - 1427-
DESCRIPTION- LIST ET AL., J. CLIN. ONCOL., (1990), vol. 8-
DESCRIPTION- LOWE; CHENG, DRUGS OF THE FUTURE, (1992), vol. 17, no. 9, pages 799 - 807-
DESCRIPTION- LOWE, EXP. OPIN. THER PATENTS, (1998), vol. 8, pages 1309 - 1332-
DESCRIPTION- MILLAR ET AL., LANCET, (1989), vol. 2, pages 712 - 714-
DESCRIPTION- MONTO ET AL., BLOOD, (1990), vol. 79, page 2670-
DESCRIPTION- MULLER ET AL., BIOORG. & MED CHEM LETT, (1998), vol. 8, pages 2669 - 2674-
DESCRIPTION- MULLER ET AL., J. MED CHEM., (1996), vol. 39, page 3238-
DESCRIPTION- NICHOLSEN ET AL., TRENDS PHARMACO. SCI., (1991), vol. 12, page 19-
DESCRIPTION- PIGNET ET AL., NATURE, (1990), vol. 344, pages 245 - 247-
DESCRIPTION- POLI ET AL., PROC. NATL. ACAD. SCI., (1990), vol. 87, pages 782 - 784-
DESCRIPTION- POLL ET AL., AIDSRES. HUM. RETROVIRUS, (1992), pages 191 - 197-
DESCRIPTION- POLL ET AL., PROC. NAT. ACAD. SCI., (1990), vol. 87, pages 782 - 785-
DESCRIPTION- RICE ET AL., SCIENCE, (1989), vol. 246, pages 1303 - 1306-
DESCRIPTION- The Merck Manual, (1999), page 953-
DESCRIPTION- TRACEY ET AL., NATURE, (1987), vol. 330, pages 662 - 664-
DESCRIPTION- VERGHESE ET AL., JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1995), vol. 272, no. 3, pages 1313 - 1320-
DESCRIPTION- VON DULLEMEN ET AL., GASTROENTEROLOGY, (1995), vol. 109, pages 129 - 135-
DESCRIPTION- WILEN, S. H. ET AL., TETRAHEDRON, (1977), vol. 33, page 2725-
DESCRIPTION- WILEN, S. H., Tables of Resolving Agents and Optical Resolutions, UNIV. OF NOTRE DAME PRESS, (1972), page 268-
OPPOSITION- Anonymous, "Development of New stereoisomeric drugs", FDA Guideline, (19920500), pages 1 - 7, XP055645997-
OPPOSITION- Anonymous, "Investigation of Chiral Active Substances", (19930000), pages 381 - 391-
OPPOSITION- Anonymous, "Investigation of chiral active substances", EMA guidelines 3CC29a, (19931000), pages 1 - 10, XP055645934-
OPPOSITION- Anonymous, "Investigation of chiral active substances", EMA guidelines 3CC29a, (19940400), pages 381 - 391, XP055645934-
OPPOSITION- Anonymous, "Ultron ES-OVM Column: A bonded Ovomucoid Protein Column for Direct HPLC Separation of Chiral Compounds", TECHNICAL REPORT, pages 1 - 12, URL: https://web.archive.org/web/19980215003756 / http://www.mac-mod.com/tr/93061-tr.html, (19980215), XP055646020-
OPPOSITION- Anonymous, "ZORBAX Ultron ES Chiral Columns", Mac Mod, (19980215), pages 1 - 2, URL: https://web.archive.org/web/19980215003756 /http://www.mac-mod.com/catalog/chiral.html, XP055646026-
OPPOSITION- "apremilast", WIKIPEDIA, (19092019), XP055645916-
OPPOSITION- "apremilast", Wikipedia, (20190918), XP055645916-
OPPOSITION- A.R. GENNARO et al., "chromatography", Remington: The Science and Practice of Pharmacy, (20000000), page 605, XP055646337-
OPPOSITION- ARIENS et al., "stereochemistry a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology", Eur. J. Clin. Pharmacol., (19840000), vol. 26, pages 663 - 668, XP055646360-
OPPOSITION- B. HUGHES et al., "THE INHIBITION OF ANTIGEN-INDUCED EOSINOPHILIA AND BRONCHOCONSTRICTION BY CDP840, A NOVEL STEREO-SELECTIVE INHIBITOR OF PHOSPHODIESTERASE TYPE 4", British Journal of Pharmacology, (19960000), vol. 118, pages 1183 - 1191, XP000926597-
OPPOSITION- Bibiana Bielekova et al., "Treatment with phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis", Multiple Sclerosis Journal, (20090923), pages 1 - 2, XP055466489-
OPPOSITION- Bibiana Bielekova et al, "Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis /Abstract/", Multiple Sclerosis Journal, (200-0923), XP055466489-
OPPOSITION- "Biological Signifcance of Enantiomeric Purity of Drugs", CHIRALITY, (19930000), vol. 5, pages 350 - 355, XP055650621-
OPPOSITION- "Development of New Stereoisomeric Drugs", FDA guidelines, (19920105), pages 1 - 6, XP055645997-
OPPOSITION- DIRK T. WITTE et al., "Development and registration of chiral drugs", Pharmacy World & Science, (19930000), vol. 15, no. 1, pages 10 - 16, XP055646066-
OPPOSITION- DYKE H et, "update of the therapeutic potential of PDE4 inhibitors", EXPERT OPINION, XP008002007-
OPPOSITION- FERNANDEZ-MARTINEZ et al., "chapter 1 Thalidomide and its Analogs: A Potential Immunomodulatory Alternative for Treating Liver Diseases and Cirrhosis", Liver Diseases and Cirrhosis, (20110000), vol. 1, pages 1 - 29, XP055646348-
OPPOSITION- Gary, "Guidance For Industry stereochemical issues in chiral drug development", (20000000), pages 1 - 12, XP055254269-
OPPOSITION- GENOVESE et al., "Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study /Abstract/", Arthritis & Rheumatology, (20150700), XP055466494-
OPPOSITION- GENOVESE et al., "Apremilast in patients with active rheumatoid arthrtis: a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study", Arthritis & Rheumatology, (20150700), pages 1703 - 1710, XP055466494-
OPPOSITION- Genovese Mark, Et Al., "Apremilast in Patients with Active Rheumatoid Arthritis: A Phase II, Multicenter, randomized, Double-Blind, Placebo-Controlled, Parallel-Group study", Arthritis & Rheumatology, (20150626), vol. 67, no. 7, pages 1 - 13, XP055466494-
OPPOSITION- GENOVESE MC et al., "Apremilast in patients with active rheumatoid arthritis: A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study", Arthritis & Rheumatology, (20150000), vol. 67, no. 7, pages 1703 - 1710, XP055466494-
OPPOSITION- HEWLETT PACKARD, "Consumables and Accessories Chemical Analysis", (19980000), pages 1 - 3, XP055646032-
OPPOSITION- "Investigation of Chiral Active Substances", EMA guidelines 3CC29a, (19940000), pages 381 - 391, URL: https://www.ema.europa.eu/en/investigation-chiral-active-substances, XP055645934-
OPPOSITION- Jack Cush, "POSTURE Study: Apremilast Fails in Ankylosing Spondylitis", RheumNow- Rheumatology News & Information, (20171215), pages 1 - 4, XP055466481-
OPPOSITION- JAQUES et al., "formation and separation of diastereomers", Enantiomers, Racemates, and Resolutions, (19810000), pages 251 - 261, XP055646338-
OPPOSITION- KELLER et al., "Synthesis and structure-Activity Relationship of N-Arylrolipram Derivatives as Inhibitors of PDE4 Isozymes", Chem. Pharm Bull., (20010000), vol. 49, pages 1009 - 1017, XP055645917-
OPPOSITION- KELLER, T. H. et al., "Synthesis and structure-Activity Relationship of N-Arylrolipram Derivatives as Inhibitors of PDE4 Isozymes", Chem. Pharm. Bull., (20010000), vol. 49, no. 8, pages 1009 - 1017, XP055645917-
OPPOSITION- K. M. KIRKLAND et al., "Optimized HPLC separations of racemic drugs using an ovomucoid protein-based chiral column", LC-GC, (19920000), vol. 10, no. 4, pages 322 - 326, XP055646009-
OPPOSITION- L. R. SNYDER et al., Practical HPLC Method Development, Hoboken NJ, USA, (19970000), XP055646322-
OPPOSITION- MICHAEL GROSS, "Chapter 34. Significance of Drug Stereochemistry in Modern Pharmaceutical Research and Development", Annual report in medicinal chemistry, (19890000), vol. 25, pages 323 - 330, XP002150744-
OPPOSITION- "Molecular modeling (computer-aided drug design)", Textbook of Organic Medicinal and Pharmaceutical Chemistry, (19980000), pages 33 - 34, XP055649449-
OPPOSITION- NANCY WALSH, "otezla Disappoints in RA - Efficacy of apremilast in rheumatoid arthritis no different from placebo", (20150325), URL: www.medpagetoday.com/rheumatology/arthritis/50659>, XP055466491-
OPPOSITION- NANCY WALSH, "- Otezla Disappoints in RA - Efficacy of apremilast in rheumatoid arthritis no different from placebo", MEDPAGE TODAY@, (20150325), XP055466491-
OPPOSITION- NEWMAN, "section 4", Optical Resolution Procedures for chemical compounds, (19840000), pages 1 - 3 and 583-590, XP055646345-
OPPOSITION- NIEUWENHUIJZEN, J.W., "Resolutions with families of resolving agents: principles and practice", Thesis, (20020000), pages 24 - 46, XP055650625-
OPPOSITION- "Otezla Disappoints in RA - Efficacy of apremilast in rheumatoid arthritis no different from placebo", MEDPAGETODAY, (20150325), pages 1 - 4, XP055466491-
OPPOSITION- S. ANDERSSON et al., "Preparative chiral chromatographic resolution of enantiomers in drug discovery", J. Biochem. Biophys. Methods, (20020000), vol. 54, no. 1-3, pages 11 - 23, XP027300578-
OPPOSITION- SATINDER AHUJA et al., "An Overview, in: Ahuja, Chiral Separations by Liquid Chromatography", SATINDER AHUJA et al., ACS Symposium Series, (19910000), pages 1 - 26, XP055646014-
OPPOSITION- SOUNESS et al., "Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFa generation from human monocysts by interacting with a 'low- affinity' phosphodiesterase 4 conformer", British Journal of Pharmacology, (19960000), vol. 118, pages 649 - 658, XP055650622-
OPPOSITION- WAINER I W, "Analytical Methods and Pharmacology", Drug Stereochemistry, (19930000), pages 167 - 174, XP008113357-
OPPOSITION- WALSH N, "Efficacy of apremilast in rheumatoid arthritis no different from placebo", Otezla Disappoints in RA, (20150000), pages 1 - 4, XP055466491-
OPPOSITION- WALSH, "Otezla Disappoints in RA - Efficacy of apremilast in rheumatoid arthritis no different from placebo", Medpage Today, (20150325), XP055466491-
OPPOSITION- WILEN, Tables of Resolving Agents and Optical Resolution, (19720000), page 24, 25, 142 and 143-
OPPOSITION- WNENDT, S. et al., "Enantioselective Inhibition of TNF-a Release by Thalidomide and Thalidomide-Analogues", Chirality, (19960000), vol. 8, pages 390 - 396, XP002074569-
OPPOSITION- B. WALDECK, "Biological significance of the enantiomeric purity of drugs", Chirality, (19930000), vol. 5, pages 350 - 355, XP055406849
OPPOSITION- B. WALDECK et al., "Biological significance of the enantiomeric purity of drugs", Chirali- ty, (19930000), vol. 5, no. 5, doi:10.1002/chir.530050514, pages 350 - 355, XP055406849
OPPOSITION- WALDECK, "Biological significance of the enantiomeric purity of drugs", Chirality, vol. 5, pages 350 - 355, XP055406849
OPPOSITION- NUGGEHALLY R. SRINIVAS et al., "Enantiomeric Drug development: issues, considerations and regulatory requirements", Journal of pharmaceutical sciences, (20010900), vol. 90, no. 9, pages 1205 - 1215, XP055645979
OPPOSITION- R. BHUSHAN et al., "Resolution of enantiomers of ibuprofen by liquid chromatography: a review", Biomed Chromatogr., (19980000), vol. 12, no. 6, doi:10.1002/(SICI)1099-0801(199811/12)12:6<309::AID-BMC763>3.0.CO;2-K, pages 309 - 316, XP002668423
OPPOSITION- WILLIAMS et al., "Enantiomers in arthritic disorders", Pharmac. Ther., (19900000), vol. 46, pages 273 - 295, XP023850665
OPPOSITION- WILLIAMS, K. M., "Enantiomers in arthritic disorders", Pharmacology & Therapeutics, (19900000), vol. 46, doi:10.1016/0163-7258(90)90095-J, pages 273 - 295, XP023850665
OPPOSITION- E. FRANCOTTE et al., "Preparative chromatographic separation of enantiomers", Journal of Chromatography, (19920000), vol. 576, pages 1 - 45, XP026538520
OPPOSITION- C.H. LOCHMUELLER et al., "Chromatographic resolution of enantiomers selective review", J. Chromatogr., (19750000), vol. 113, no. 2, doi:10.1016/S0021-9673(00)95302-0, pages 283 - 302, XP000615118
OPPOSITION- K. M. KIRKLAND et al., "Comparison of a new ovomucoid and a second-generation α1-acid glycoprotein-based chiral column for the direct high-performance liquid chromatography resolution of drug enantiomers", Journal of Chromatography, (19910000), vol. 545, pages 43 - 58, XP055646006
OPPOSITION- A. MEDVEDOVICI et al., "Chiral packed column subcritical fluid chromatography on poly- saccharide and macrocyclic antibiotic chiral stationary phases", J, of Chromatography A, (19971017), vol. 785, no. 1-2, pages 159 - 171, XP004097560
OPPOSITION- L. MILLER et al., "Preparative chromatographic resolution of enantiomers using polar organic solvents with polysaccharide chiral stationary phases", J. Chromatogr., (19990000), vol. 865, no. 1- 2, doi:10.1016/S0021-9673(99)00743-8, pages 211 - 226, XP003015405
OPPOSITION- G.W. MULLER et al., "Thalidomide Analogs and PDE4 Inhibition", Bioorganic & Medicinal Chemistry Letters, vol. 8, no. 1998, doi:10.1016/S0960-894X(98)00475-2, pages 2669 - 2674, XP002938448
OPPOSITION- MULLER et al., "- Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production", Bioorg. Med. Chem. Lett., (19990000), vol. 9, pages 1625 - 1630, XP002222981
OPPOSITION- Z. HUANG et al., "The next generation of PDE4 inhibitors", Current Opinion in Chemical Biology, (20010000), vol. 5, doi:10.1016/S1367-5931(00)00224-6, pages 432 - 438, XP002325704
OPPOSITION- H. D. DEWITT et al., "N-Acylamino acids, a new class of resolving agents", JACS, (19510000), vol. 73, pages 5782 - 3, XP002026388
OPPOSITION- KLEINMAN et al., "Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNFalpha inhibitory activity of two series of Rolipram analogues: implications for a new active site model of PDE4", J. Med. Chem., (19980000), vol. 41, pages 266 - 270, XP002093975
OPPOSITION- J.E. SOUNESS et al., "Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformer", British Journal of Pharmacology, (19960000), vol. 118, pages 649 - 658, XP055406854
OPPOSITION- SOUNESS et al., "Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformer", British J. Pharmacol., (19960000), vol. 118, pages 649 - 658, XP055406854
OPPOSITION- SOUNESS et al., "Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformer", Br. J. Pharmacol., vol. 118, no. 3, pages 649 - 658, XP055406854
OPPOSITION- PFEIFFER ET AL., "Optical isomerism and pharmacological action , a generalization", Science, (19560000), vol. 3210, pages 29 - 31, XP055406821
OPPOSITION- T.H. KELLER et al., "Synthesis and structure- activity relationship of N-Arylrolipram derivatives as inhibitors of PDE4 Isozymes", Chem. Pharm. Bull., (20010000), vol. 49, pages 1009 - 1017, XP055645955
OPPOSITION- ISLAM et al., "Pharmacological Importance of Stereochemical Resolution of Enantiomeric Drugs", Drug Safety, (19970000), vol. 17, no. 3, pages 149 - 165, XP055646335
OPPOSITION- M.R. ISLAM et al., "Pharmacological Importance of Stereochemical Resolution of Enan- tiomeric Drugs", Drug Safety, (19970000), vol. 17, no. 3, pages 149 - 165, XP055646335

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents